Tag: chronic spontaneous urticaria market revenue

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the chronic spontaneous urticaria market grown in recent years?

The chronic spontaneous urticaria market has experienced significant growth in recent years. It is expected to grow from $2.06 billion in 2024 to $2.23 billion in 2025, at a compound annual growth rate (CAGR) of 8.6%. This growth can be attributed to advancements in diagnostic tools, rising awareness among healthcare providers, patient support groups, ongoing research and clinical trials exploring new treatments, and increasing healthcare spending.

How is the chronic spontaneous urticaria market size expected to evolve during the forecast period?

The chronic spontaneous urticaria market is projected to grow to $3.08 billion by 2029 at an 8.4% CAGR. This growth is driven by a higher number of diagnosed cases, expanding patient pools, and better healthcare infrastructure. Trends include innovations in technology, advancements in biological therapies, personalized medicine, telemedicine, AI, and machine learning, as well as increasing drug approvals.

Get your chronic spontaneous urticaria market report here!

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which key drivers are propelling the chronic spontaneous urticaria market’s growth?

Increasing alcohol consumption is expected to propel the growth of the chronic spontaneous urticaria market. Rising alcohol consumption, driven by social norms and stress, can exacerbate symptoms of chronic spontaneous urticaria, such as swelling and hives. According to rehabs.UK, 55% of men and 41% of women reported weekly alcohol consumption in 2024. With increased alcohol-related hospital admissions, the demand for treatments for chronic spontaneous urticaria is rising. As alcohol consumption continues to rise, it is driving the growth of the chronic spontaneous urticaria market.

What are the market segments in the chronic spontaneous urticaria industry?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy (for Stress-Related Triggers)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Which leading companies are shaping the growth of the chronic spontaneous urticaria market?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

What key trends are currently impacting the chronic spontaneous urticaria market’s development?

Companies in the chronic spontaneous urticaria market are developing next-generation treatments like Briquilimab (JSP191) to enhance efficacy and reduce dosing frequency. Briquilimab is a monoclonal antibody that targets CD47 to treat chronic spontaneous urticaria. For example, in November 2023, US-based Jasper Therapeutics dosed its first patient in a Phase 1b/2a clinical trial to evaluate Briquilimab’s safety and effectiveness for chronic spontaneous urticaria, aiming to improve symptoms and quality of life for patients with this condition.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16651

Which geographic areas are influencing the growth of the chronic spontaneous urticaria market?

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Chronic Lower Back Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Chronic Cough Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Projected Compound Annual Growth Rate (CAGR) of the Chronic Spontaneous Urticaria Market from 2025 to 2034, and What Factors Influence It?

There has been significant expansion in the chronic spontaneous urticaria market in the past few years. The market is forecasted to increase from $2.06 billion in 2024 to $2.23 billion in 2025, representing a compound annual growth rate (CAGR) of 8.6%. This growth, during the historical period, is due to the development of enhanced diagnostic instruments, increased awareness among healthcare, patient support groups, and advocates, current research and clinical trials investigating new treatments, and rising health care spending.

In the coming years, the market size of chronic spontaneous urticaria is projected to experience substantial growth, reaching $3.08 billion by 2029 with a compound annual growth rate (CAGR) of 8.4%. This surge during the forecast period is likely due to the escalating numbers of diagnosed cases of CSU, an enlarging patient pool, improvements in healthcare infrastructure, a supportive regulatory context, patient-focused treatment models, and economic development in rising markets. Significant trends for the forecast period encompass technological breakthroughs, progressive biological therapies, tailored medicine, telehealth and digital healthcare, improved diagnosis tools, the application of AI and machine learning, and a rise in drug authorizations and introductions.

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Chronic Spontaneous Urticaria Market?

The expected growth in the chronic spontaneous urticaria market is anticipated to be driven by rising alcohol consumption. The surge in alcohol intake can be linked to various elements such as societal expectations, stress, promotional activities, cost-effectiveness, and easy accessibility. Drinking alcohol may intensify chronic spontaneous urticaria symptoms in certain individuals, leading to an uptick in hives and inflammation. As per data from rehabs.UK, a British organization that provides assistance and advice for overcoming addiction, in February 2024, 55% of males reported consuming alcohol on a weekly basis, while the figure stood at 41% for females. Moreover, 8% of males and 5% of females reported nearly daily alcohol consumption. From 2021 to 2022, alcohol-related hospital admissions amounted to 342,795, equating to a rate of 626 admissions per 100,000 individuals. Consequently, the escalating alcohol consumption is fueling the expansion of the chronic spontaneous urticaria market.

Get Your Free Sample of the Global Chronic Spontaneous Urticaria Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Who Are the Leading Players Fueling Growth in the Chronic Spontaneous Urticaria Market?

Major companies operating in the chronic spontaneous urticaria market are:

• F. Hoffmann-La Roche Ltd.

• Merck & Co. Inc.

• AbbVie Inc.

• Bayer AG

• Sanofi SA

What Are the Emerging Trends Shaping the Future of the Chronic Spontaneous Urticaria Market?

Leading firms in the chronic spontaneous urticaria market are focusing on the development of advanced Briquilimab (JSP191) to improve the efficacy of treatment and reduce the need for frequent doses. Briquilimab (JSP191) is a next-generation monoclonal antibody that specifically targets and eradicates certain immune cells, mainly those targeting CD47, in conditions like chronic spontaneous urticaria. For example, in November 2023, Jasper Therapeutics Inc., a clinical-stage biotech firm based in the US, disclosed its first patient dosage in a Phase 1b/2a clinical trial of Briquilimab for chronic spontaneous urticaria (CSU). This milestone is crucial in determining the safety and efficiency of Briquilimab, a next-generation monoclonal antibody targeting CD47, in addressing this recurring skin condition characterized by hives and itching. The study aims to evaluate the ability of Briquilimab to alleviate symptoms and enhance the life quality of those battling CSU.

Get Instant Access to the Global Chronic Spontaneous Urticaria Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Segments of the Chronic Spontaneous Urticaria Market Hold the Most Potential for Future Development?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy (for Stress-Related Triggers)

Which Regions Are Driving Growth in the Chronic Spontaneous Urticaria Market?

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Features of the Chronic Spontaneous Urticaria Market?

Chronic spontaneous urticaria (CSU) is a skin condition characterized by the recurrent appearance of hives (raised, red, itchy welts) and angioedema (swelling) lasting for more than six weeks, without an identifiable external trigger. The exact cause of CSU is often unknown, but it may involve an autoimmune component where the body’s immune system mistakenly attacks healthy skin cells. Treatment focuses on symptom management, primarily using antihistamines and, in more severe cases, other medications such as biologics.

Browse Through More Similar Reports By The Business Research Company:

Chronic Lower Back Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Chronic Cough Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What Will Be the Growth Trajectory of the Chronic Spontaneous Urticaria Market from 2024 to 2033?
The chronic spontaneous urticaria market has shown strong growth, expected to increase from $1.90 billion in 2023 to $2.06 billion in 2024, achieving a CAGR of 8.3%. Growth factors include improved diagnostic tools, heightened awareness among healthcare providers, patient advocacy initiatives, ongoing studies for new therapies, and increasing healthcare expenditures.

The chronic spontaneous urticaria market is expected to experience significant growth, reaching $2.84 billion by 2028 at a CAGR of 8.4%. This growth is attributed to a rise in diagnosed cases, a growing patient population, improved healthcare infrastructure, supportive regulatory environments, and economic growth in emerging markets. Trends will include technological innovations, advancements in biological therapies, and increased drug approvals.

Claim Your Free Sample of the Global Chronic Spontaneous Urticaria Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

What Are the Primary Growth Drivers for the 2024 Chronic Spontaneous Urticaria Market Analysis: Market Size, Key Drivers, and Segment Insights Market?
The increase in alcohol consumption is expected to propel the chronic spontaneous urticaria market. Social norms and stress contribute to rising alcohol use, which can worsen symptoms in some individuals. According to rehabs.UK, 55% of men and 41% of women reported weekly alcohol consumption in early 2024, with a notable number of hospital admissions linked to alcohol.

What Are the Defining Segments of the Chronic Spontaneous Urticaria Market?
1) By Treatment: Medication; Phototherapy; Other Treatments
2) By Route Of Administration: Oral; Topical; Parenteral; Other Routes Of Administration
3) By Diagnosis: Physical Examination; Blood Test; Allergy Test; Other Diagnosis
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

What Trends Are Revolutionizing Standards in the Chronic Spontaneous Urticaria Market?
In the chronic spontaneous urticaria market, companies are developing next-generation monoclonal anti-IgE antibodies to enhance treatment efficiency. For example, in January 2021, Novartis AG received FDA approval for ligelizumab, the first treatment designated as a Breakthrough Therapy for chronic spontaneous urticaria.

Order Now for Fast Delivery of Your Chronic Spontaneous Urticaria Market Report!
https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

What Regions Are Propelling Growth in the Chronic Spontaneous Urticaria Industry?
North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Chronic Spontaneous Urticaria Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the chronic spontaneous urticaria market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Chronic Spontaneous Urticaria Market Include

1. Chronic Spontaneous Urticaria Market Executive Summary
2. Chronic Spontaneous Urticaria Market Segments
3. Chronic Spontaneous Urticaria Market Size And Template Market Growth Rate
4.  Key Chronic Spontaneous Urticaria Market Trends
5. Major Chronic Spontaneous Urticaria Market Drivers
……
25. Key Mergers And Acquisitions In The Chronic Spontaneous Urticaria Market
26. Top Chronic Spontaneous Urticaria Companies
27. Chronic Spontaneous Urticaria Market Opportunities And Strategies
28. Chronic Spontaneous Urticaria Market, Conclusions And Recommendations
29. Appendix

Discover Related Reports by The Business Research Company:
Chronic Disease Management Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Chronic Lower Back Pain Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: